Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase 3 study.

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Findings from a new Dartmouth-led study, published in the journal mBio, highlight key differences in the gut microbiome (communities of bacteria) of infants with cystic fibrosis (CF) compared to that ...

An imbalance in gene activity within two types of immune cells explains why idiopathic pulmonary fibrosis (IPF) progresses but in people who develop lung fibrosis after a severe COVID-19 infection, ...

COPD is a progressive lung disease with mild symptoms in the early stages that gradually worsen. Early diagnosis and treatment can help preserve lung function. People with COPD often have trouble ...

Changes of lung functions and 6MWD at different time points after REGEND001 treatment. (A-D) The plots indicated mean (S.E.M.) changes from baseline in absolute value of DLCO/VA percentage to ...

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

Lung cancer is one of the most common types of cancer in the United States and a leading cause of cancer deaths. However, the timeline of how the disease progresses can vary based on several factors.

Objective: Oral submucous fibrosis (OSF) is a chronic oral mucosal disease, which exerts a profound impact on patients’ daily life and currently lacks efficacious therapeutic interventions.